eliquis apixaban eliquis apixaban eliquis apixaban logo

This information is intended for healthcare professionals based in the UK.

If you are not a healthcare professional in the UK, please click here.

For Prescribing and Adverse Event reporting information, click here.

desk-img mob-img

Choose ELIQUIS (apixaban) for your patients with NVAF

ELIQUIS – AN ORAL, DIRECT FACTOR XA INHIBITOR – IS INDICATED FOR:

  • Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥75 years; hypertension; diabetes mellitus; symptomatic heart failure
    (NYHA class ≥II).1

In patients with NVAF, ELIQUIS is the only factor Xa inhibitor to demonstrate both:

  • Superiority on the prevention of stroke / systemic embolism vs. warfarin2-4
  • Superiority on the incidence of major bleeding vs. warfarin2-4
Purple information icon ELIQUIS (apixaban) SmPC

Please click here to access the ELIQUIS SmPC.

Purple information icon ELIQUIS (apixaban) Patient Information Leaflet

Please click here to access the ELIQUIS Patient Information Leaflet.

NVAF = Non-Valvular Atrial Fibrillation   
NYHA = New York Heart Association   
TIA = Transient Ischaemic Attack

References

  1. ELIQUIS® (apixaban) Summary of Product Characteristics.
  2. Granger CB et al. N Engl J Med 2011; 365: 981–992.
  3. Patel MR et al. N Engl J Med 2011; 365: 883–891.
  4. Giugliano RP et al. N Engl J Med 2013; 369: 2093–2104.